|
Q2 FY2013
As of Jun 30, 2013
|
Q1 FY2013
As of Mar 31, 2013
|
Q4 FY2012
As of Dec 31, 2012
|
Q3 FY2012
As of Sep 30, 2012
|
Q2 FY2012
As of Jun 30, 2012
|
Q1 FY2012
As of Mar 31, 2012
|
Q4 FY2011
As of Dec 31, 2011
|
Q3 FY2011
As of Sep 30, 2011
|
Q2 FY2011
As of Jun 30, 2011
|
Q1 FY2011
As of Mar 31, 2011
|
Q4 FY2010
As of Dec 31, 2010
|
Q3 FY2010
As of Sep 30, 2010
|
Q2 FY2010
As of Jun 30, 2010
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||
| Current assets: | |||||||||||||
| Cash and cash equivalents | |||||||||||||
| Marketable securities, current | |||||||||||||
| Restricted cash | |||||||||||||
| Accounts receivable, net | |||||||||||||
| Receivable from collaboration partners | |||||||||||||
| Inventory | |||||||||||||
| Deferred tax asset | |||||||||||||
| Prepaid expenses and other current assets | |||||||||||||
| Total current assets | |||||||||||||
| Marketable securities, non-current | |||||||||||||
| Property and equipment, net | |||||||||||||
| Finite - lived intangible assets, net | |||||||||||||
| Intangible assets - in-process research and development | |||||||||||||
| Goodwill | |||||||||||||
| Other assets | |||||||||||||
| Total assets | |||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||||
| Current liabilities: | |||||||||||||
| Accounts payable | |||||||||||||
| Accrued liabilities | |||||||||||||
| Accrued clinical trials and related expenses | |||||||||||||
| Accrued compensation | |||||||||||||
| Escrow account liability | |||||||||||||
| Lease termination exit costs, Current | |||||||||||||
| Deferred revenue | |||||||||||||
| Other current liabilities | |||||||||||||
| Total current liabilities | |||||||||||||
| Accounts payable and accrued liabilities | |||||||||||||
| Liability for contingent consideration, current | |||||||||||||
| Lease termination exit costs, current | |||||||||||||
| Escrow account liability | |||||||||||||
| Convertible senior notes due 2016 | |||||||||||||
| Liability for contingent consideration | |||||||||||||
| Liability for contingent consideration, non-current | |||||||||||||
| Deferred tax liability | |||||||||||||
| Other liabilities | |||||||||||||
| Lease termination exit costs, non-current | |||||||||||||
| Stockholders' equity: | |||||||||||||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued and outstanding | |||||||||||||
| Common stock, $0.001 par value; 200,000,000 shares authorized; 73,056,158 and 67,479,518 shares issued and outstanding as of June 30, 2013 and December 31, 2012, respectively | |||||||||||||
| Additional paid-in capital | |||||||||||||
| Receivable from stock option exercises | |||||||||||||
| Accumulated other comprehensive loss | |||||||||||||
| Accumulated other comprehensive income (loss) | |||||||||||||
| Accumulated deficit | |||||||||||||
| Total stockholders' equity | |||||||||||||
| Total liabilities and stockholders' equity | |||||||||||||
Loading...
